How does zanubrutinib fare in treatment of B-cell malignancies?

Abstract

Now that effective, non-cytotoxic therapies are more embedded in the treatment of indolent B-cell malignancies (according to country-specific reimbursement arrangements), patients have a notable range of adverse events, and physicians are having to navigate the balance between efficacy and toxicity. Fortunately, clinical trial follow-up has gained longevity, and real-world evidence that can inform clinical practice is increasing.